- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05308316
Sugars in Cigarettes
February 6, 2026 updated by: Masonic Cancer Center, University of Minnesota
Impact of Sugars on Tobacco Product Toxicity and Abuse Liability
The aim of this study is to investigate the impact of sugar levels in cigarette tobacco on cigarette abuse liability and appeal.
Participants will attend several clinic visits to smoke cigarettes with different levels of sugars and will complete multiple questionnaires to assess their experiences.
Each of the sessions will be separated by at least 48 hours but not more than 5 days.
The hypothesis is that the measures collected in this study will indicate lower abuse liability for cigarettes with lowest sugar content.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
30
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- Masonic Cancer Center at University of Minnesota
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
21 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Male or female age 21 years or older
- Smoking cigarettes that have been evaluated to have medium levels of sugar content
- No quit attempts in the past month nor intentions to quit smoking in the next month
- Participants are in good physical health (no unstable medical conditions) as determined by the licensed medical professional
- Participants are in stable, good mental health (e.g. not currently, within the past 6 months, experiencing unstable or untreated psychiatric diagnosis) as determined by the licensed medical professional
- Stable vitals sign measurements (systolic BP ≤ 160 and >90 mmHg, diastolic BP ≤ 100 and >50 mmHg and heart rate ≤105 and > 45 bpm) as determined by the licensed medical professional
- Participants must be able to read for comprehension or completion of study documents (confirmed during informed consent process)
- Participants have provided written informed consent to participate in the study.
Exclusion Criteria:
- Significant immune system disorders, respiratory diseases, kidney or liver diseases or any other medical disorders that may affect biomarker data as determined by the licensed medical professional
- Women who are pregnant or nursing or planning to become pregnant.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Impact of Sugar Content
Participants will be asked to attend 4 laboratory sessions during which they will smoke their usual brand (UB) cigarettes and then one of three study cigarettes with low, medium and high levels of sugar in separate sessions, using a within-subject design with conditions counterbalanced determined by a Latin square.
In each session, smokers will be asked to smoke a cigarette in a standardized manner (10 puffs,30 second interval between puffs) and 1 hour later, ad libitum.
Each of the sessions will be separated by at least 48 hours but not more than 5 days.
|
Winston brand cigarettes will be modified by adding sucrose to each cigarette at 2 levels so that the amount of total (originally present and added) sugar content in these cigarettes matches median and highest levels found in popular cigarette brands.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Impact of Cigarette Sugar Content on Product Satisfaction.
Time Frame: At each session, 2 hours post all puffs (assessed at all 4 sessions, each session was up to 4 hours, and all sessions took place between 2-3 weeks post enrollment, separated by 2-5 days)
|
Product satisfaction will be measured using Modified Cigarette Evaluation Questionnaire (mCEQ).
The mCEQ will involve 5 items rated on a 7-point Likert scale ranging from 1 "Not at all" to 7 "Extremely".
A lower score would indicate less satisfaction, enjoyment smoking the assigned cigarette.
|
At each session, 2 hours post all puffs (assessed at all 4 sessions, each session was up to 4 hours, and all sessions took place between 2-3 weeks post enrollment, separated by 2-5 days)
|
|
Impact of Sugar Content on Behavioral Outcomes Using the Multiple Choice Procedure Task.
Time Frame: At each session, 2 hours post all puffs (assessed at all 4 sessions, each session was up to 4 hours, and all sessions took place between 2-3 weeks post enrollment, separated by 2-5 days)
|
Outcome measures for the Multiple Choice Procedure task are breakpoint (price at which participant switches from the study cigarette to money), elasticity (changes in consumption in response to changes in price); intensity (consumption at $0.00 price); Omax (maximum expenditure); and Pmax (price corresponding to Omax).
Multiple Choice Procedure determines the price at which participants would switch from product to money, called the crossover point.
Products with lower abuse liability tend to have a lower crossover point.
|
At each session, 2 hours post all puffs (assessed at all 4 sessions, each session was up to 4 hours, and all sessions took place between 2-3 weeks post enrollment, separated by 2-5 days)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Other Subjective and Behavioral Measures: Effects/Liking
Time Frame: At each session, 2 hours post all puffs (assessed at all 4 sessions, each session was up to 4 hours, and all sessions took place between 2-3 weeks post enrollment, separated by 2-5 days)
|
Drug Effects/Liking Questionnaire is used to assess abuse liability of drugs and measures overall desirability of the product and intention to use in the future.
Range from 0 - 100.
A score of 0 being the weakest possible score, with 100 being the strongest score.
Answers to questionnaire are averaged to calculate a composite score.
|
At each session, 2 hours post all puffs (assessed at all 4 sessions, each session was up to 4 hours, and all sessions took place between 2-3 weeks post enrollment, separated by 2-5 days)
|
|
Other Subjective and Behavioral Measures: Sensory Effect of Smoking
Time Frame: At each session, 2 hours post all puffs (assessed at all 4 sessions, each session was up to 4 hours, and all sessions took place between 2-3 weeks post enrollment, separated by 2-5 days)
|
Sensory Effect of Smoking Questionnaire (SESQ) uses a 7-point Likert scale ranging from 1 "Not at all" to 7 "Extremely", with a lower score indicating lower favorability, strength and effect of the cigarette on a participant.
Five questions in this SESQ used for this study deal with the sensation of the strength of smoke impact on tongue, nose, mouth and throat, windpipe, and chest.
Responses to each question were averaged to calculate final score.
Total average minimum is one (lower effect) and total average maximum is seven (higher effect).
|
At each session, 2 hours post all puffs (assessed at all 4 sessions, each session was up to 4 hours, and all sessions took place between 2-3 weeks post enrollment, separated by 2-5 days)
|
|
To Evaluate the Impact of Sugar Content on Smoking Intensity
Time Frame: At each session, 2 hours post all puffs (assessed at all 4 sessions, each session was up to 4 hours, and all sessions took place between 2-3 weeks post enrollment, separated by 2-5 days)
|
Measure the amount of nicotine levels in the spend filters during the controlled puffing pattern.
Nicotine levels will be determined through LC/MS.
|
At each session, 2 hours post all puffs (assessed at all 4 sessions, each session was up to 4 hours, and all sessions took place between 2-3 weeks post enrollment, separated by 2-5 days)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Irina Stepanov, PhD, University of Minnesota, Division of Environmental Health Sciences
- Principal Investigator: Dorothy Hatsukami, Masonic Cancer Center Tobacco Research Programs
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 24, 2022
Primary Completion (Actual)
October 13, 2023
Study Completion (Actual)
October 9, 2025
Study Registration Dates
First Submitted
February 25, 2022
First Submitted That Met QC Criteria
March 25, 2022
First Posted (Actual)
April 4, 2022
Study Record Updates
Last Update Posted (Actual)
February 27, 2026
Last Update Submitted That Met QC Criteria
February 6, 2026
Last Verified
February 1, 2026
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2020LS236
- R01DA051005 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tobacco Use
-
Loma Linda UniversityUniversity of California, San Francisco; Riverside University Health System...RecruitingTobacco Use | Tobacco Use Cessation | Tobacco Use in ChildbirthUnited States
-
University of Mississippi Medical CenterNot yet recruitingTobacco Cessation
-
University of California, San FranciscoTobacco Related Disease Research ProgramRecruitingTobacco Cessation | Tobacco Use | Tobacco Use Cessation | Tobacco Dependence | Tobacco AbstinenceUnited States
-
Juul Labs, Inc.CompletedTobacco Use | Tobacco Smoking | Electronic Cigarette Use | Cigarette Use, ElectronicUnited States
-
Juul Labs, Inc.CompletedTobacco Use | Tobacco Smoking | Electronic Cigarette Use | Cigarette Use, ElectronicUnited States
-
Mayo ClinicNational Institute on Drug Abuse (NIDA)CompletedSmoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Cessation | Smoking, Tobacco | Smoking, CigaretteUnited States
-
Duke UniversityCompletedSmokeless Tobacco CessationUnited States
-
University of FloridaRecruitingTobacco Use | Nicotine UseUnited States
-
Claremont Graduate UniversityNational Cancer Institute (NCI)CompletedSmoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Cessation | Smoking, CigaretteUnited States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)CompletedTobacco Product Beliefs and UseUnited States
Clinical Trials on Cigarettes with added sucrose
-
Edith Cowan UniversityFlinders University; The University of Western AustraliaCompleted
-
Edith Cowan UniversityFlinders University; The University of Western AustraliaCompleted
-
University of Alabama, TuscaloosaMcCormick Science InstituteRecruitingCardiometabolic SyndromeUnited States
-
Edith Cowan UniversityFlinders University; The University of Western AustraliaNot yet recruitingHealth Risk Behaviors
-
University of TorontoActive, not recruiting
-
University of CalgaryCompletedObesity | Atrial FibrillationCanada
-
Maastricht University Medical CenterCompletedCardiovascular Disease | Hypercholesterolemia | Dietary Modification | ButtermilkNetherlands
-
Meir Medical CenterUnknown
-
Jens Rikardt AndersenRigshospitalet, DenmarkCompletedStroke | Brain Injuries | Traumatic Brain Injury | Subarachnoid Hemorrhage | Anoxic Brain Injury | NeuroinfectionsDenmark
-
Wageningen UniversityAjinomoto Co., Inc.Not yet recruitingEnergy Density | Food Intake Measurement | Sensory Testing | Umami TasteNetherlands